Murillo-Godínez G

Language: Spanish
References: 18
Page: 179-181
PDF size: 222.24 Kb.

ABSTRACT

The increased risk of cancer with the use of drugs for the treatment of other diseases, is a known fact for over half a century, but recently, the report of this problem associated with drugs such as some antihypertensives, and inhaled insulin, has been restored to a worldwide attention, the safety of treatments of scientific medicine, so it is prudent to analyze the issue in order to provide better patient care.

REFERENCES

1. Strickland PT, Kensler TW. Genesis of cancer. Environmental factors. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG. Abeloff's Clinical Oncology. Philadelphia: Churchill Livingstone, 2008;130.

2. Brawley OW, Kramer BS. Prevención y detección del cáncer. En: Fauci AS, Braunwald E, Kasper DL, Hauser SL, et al. Harrison. Principios de Medicina Interna. México: McGraw-Hill Interamericana, 2009;I:486-492.

3. Thun MJ. Epidemiología del cáncer. En: Goldman L, Ausiello D (eds.) Cecil. Tratado de Medicina Interna. Barcelona: Elsevier, 2009:1335-1340.

4. Benowitz NL. Antihipertensivos. En: Katzung BG. Farmacología básica y clínica. México: El Manual Moderno, 2007;163-185.

5. Messerli FH. Risk factors for renal cell carcinoma: hypertension or diuretics? Kidney Int 2005;67:774.

6. Lip GY, Ferner RE. Diuretic therapy for hypertension: a cancer risk? J Hum Hypertens 1999;13:421.

7. Weikert S, Boeing H, Pischon T, Weikert C, et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol 2008;167(4):438-446.

8. Berenson A. Weak sales prompt Pfizer to cancel diabetes drug. The New York Times 2007 oct. 19 (http://www.nytimes. com/2007/10/19/business/19pfizer.html?_r=1) (consultada el 27-07-2010)

9. Inhaled insulin withdrawn, owing to weak sales. Physician's First Watch 2007 oct. 22 (http://firstwatch.jwatch.org/cgi/content/ full/2007/1022/4) (consultada el 27-07-2010)

10. Higher lung cancer Incidence in Exubera ® patients. Physician's First Watch 2008 apr. 10 (http://firstwatch.jwatch. org/cgi/content/full/2008/410/3) (consultada el 27-07-2010)

11. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: metaanalysis of randomized controlled trials. Lancet Oncology 2010;11(7):627-636.

12. Nissen SE. Angiotensin-receptor blockers and cancer: urgent regulatory review needed. Lancet Oncology 2010;11(7):605-606.

13. Krumholz HM. Angiotensin-receptor blockers and cancer: An inconvenient truth? Journal Watch Cardiology 2010 jun. 13 (http://cardiology.jwatch.org/cgi/content/full/2010/613/1) (consultada el 27-07-2010).

14. Tofupill ®. CV Directo ® (http://cvdirectomexico.com/index. php?dispatch=products.view&product_id=30) (consultada el 28-07-2010)

15. Touillaud MS, Thiebaut AC, Fournier A, Niravong M, et al. Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status. Natl Cancer Inst 2007;99(6):475-486.

16. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res 1998;58(17):3833-3838.

17. González RQ. Los productos “milagrosos” sólo dañan la economía y salud de los mexicanos. 3er. Sector. Revista de reflexión 2006. (http://www.3ersector.org.mx/index. php?option=com_content&task=view&id=3366&Itemid=27) (consultada el 28-07-2010)

18. Cofepris . Secretaría de Salud. Dirección General de Comunicación Social. La Secretaría de Salud acuerda con la ANTAD, Wal-Mart y principales cadenas farmacéuticas la no venta de productos milagro. Productos milagro 2007 abr. (http://201.147.97.103/wb/cfp/buscador?cx=004846083730 663427159%3Axgjb6em1t8w&cof=FORID%3A10&ie=UTF- 8&q=tofupil&siteurl=201.147.97.103%2Fwb%2Fcfp%2Fbus cador#263) (consultada el 28-07-2010)